When Treatment Is Mitigated by Adverse Events- The Economic Impact of Treatment-Associated Adverse Events in Cirrhotic Non-Responders Treated with Boceprevir or Telaprevir and Peginterferon Alpha/Ribavirin
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.167
https://www.valueinhealthjournal.com/article/S1098-3015(13)02072-X/fulltext
Section Title :
Disease-Specific Studies
Section Order :
154
First Page :
A350
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02072-X&doi=10.1016/j.jval.2013.08.167